衰弱与妇科癌症患者围手术期及生存结局的关联:一项基于人群的研究
该研究利用加拿大安大略省全省数据库,纳入2009至2021年间因妇科恶性肿瘤接受开腹手术的21359例患者,分别用术前衰弱指数(pFI)和John Hopkins调整临床分组衰弱指标(ACG)定义衰弱。pFI定义的衰弱与30天并发症、30天及90天死亡、30天医疗费用升高和5年生存降低相关,多变量回归显示衰弱独立关联30天并发症(OR 1.92,95%CI 1.63-2.27)和较低5年生存(HR 1.27,95%CI 1.16-1.38);ACG结果相似。作者认为需要制定优化衰弱患者围手术期管理的策略。
要点
- pFI定义的衰弱患者30天并发症发生率为25.7%,非衰弱患者为7.4%。
- pFI定义的衰弱患者30天死亡率为2.9%,90天死亡率为7.1%。
- 多变量分析显示衰弱与30天并发症独立相关(OR 1.92,95%CI 1.63-2.27)。
核心结论
- pFI和ACG两种指标定义的衰弱均可预测术后并发症、死亡和5年生存等结局。
- 作者认为需要制定优化衰弱患者围手术期管理的策略。
研究设计与样本
- 基于人群的观察性回顾性队列研究,使用安大略省全省数据库。
- 纳入2009年至2021年间因妇科恶性肿瘤接受开腹手术的患者21359例。
- 衰弱分别用术前衰弱指数(pFI)和John Hopkins调整临床分组衰弱指标(ACG)定义。
主要发现
- pFI定义的衰弱患者1405例(6.6%),ACG定义的衰弱患者1144例(5.4%)。
- pFI定义的衰弱组30天并发症发生率为25.7%,非衰弱组为7.4%(p<0.0001)。
- pFI定义的衰弱组30天死亡率为2.9%,非衰弱组为0.5%;90天死亡率为7.1% vs 1.4%(p<0.0001)。
- pFI定义的衰弱组30天平均医疗费用为16478美元,非衰弱组为9306美元(p<0.0001);衰弱组5年生存中位数为3.28年,非衰弱组未达到。
- 多变量回归调整年龄、收入五分位、原发癌症、分期、手术类型和新辅助化疗后,衰弱独立关联30天并发症(OR 1.92,95%CI 1.63-2.27,p<0.0001);调整年龄、原发癌症、分期、新辅助化疗和合并症后,衰弱关联较低5年生存(HR 1.27,95%CI 1.16-1.38,p<0.0001);ACG结果相似,ROC分析显示两指标曲线下面积相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The relationship between frailty and both short- and long-term outcomes remains underexplored in gynecologic oncology (GO). We sought to evaluate the association of frailty with 30-day complications, costs and mortality, and long-term survival following surgery. METHODS: A population-based observational retrospective cohort study of patients undergoing a laparotomy for a gynecologic malignancy between 2009 and 2021 was conducted using Ontario province-wide databases. Frailty was defined using the preoperative frailty index (pFI) and the John Hopkins Adjusted Clinical Groups frailty indicator (ACG). RESULTS: Among 21,359 patients, 1405 (6.6 %) and 1144 (5.4 %) were frail using the pFI and ACG. Frailty as assessed by the pFI was associated with an increased risk of 30-daycomplications (25.7 % vs 7.4 %, p < 0.0001), 30-day mortality (2.9 % vs 0.5 %, p < 0.0001), 90-day mortality (7.1 % vs 1.4 %, p < 0.0001), 30-day mean healthcare costs ($16,478 vs $9306, p < 0.0001), and lower median 5 year-survival (3.28 years versus not reached). Frailty was independently associated with 30-day complications (OR 1.92, 95 % CI 1.63-2.27, p < 0.0001)) in multivariable regression analysis adjusting for age, income quintile, primary cancer, stage, type of surgery and neoadjuvant chemotherapy, and with lower 5-year survival (HR 1.27, 95 % CI 1.16-1.38, p < 0.0001) adjusting for age, primary cancer, stage, neoadjuvant chemotherapy and comorbidities. Results for these outcomes were similar using the ACG. The ROC analysis revealed similar area under the curve for both indices. CONCLUSIONS: Frailty as measured by both the pFI and ACG was predictive of outcomes including increased postoperative morbidity and mortality, and 5-year survival. Strategies to optimize perioperative care for frailty are required.
引用
- Nguyen JMV, Zigras T, Gayowsky A, et al. Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study. Gynecol Oncol. 2025. PMID: 40483917. doi:10.1016/j.ygyno.2025.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。